Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine

John W. Greiner, Fiorella Guadagni, Mario Roselli, Carol A. Nieroda

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Cytokine-based tumor antigen augmentation is one of the approaches researchers and clinicians are using to improve the effectiveness of MAb-directed tumor diagnosis and therapy. Other efforts encompass the use of dose-fractionation for multiple administrations of radioimmunoconjugates, exploitation of genetic engineering to construct antibody molecules with specific biological properties (i.e., altered pharmacokinetics, activation of cellular immune responses, etc.) and use of MAb-directed conjugates that can enhance tumor MAb uptake by altering tumor perfusion (7, 19). The studies summarized here as well as those from other laboratories have served as the framework for clinical investigations designed to determine the effectiveness of the interferons and other differentiation-inducing agents to alter the tumor antigen phenotype in patients. In an earlier study, patients given IFN-α had improved tumor uptake of an antimelanoma MAb(20). Subsequently, we reported that i.p. IFN-γ administration substantially upregulated TAG-72 and CEA on the surface of human tumor cells isolated from malignant ascites (21). A seminal investigation showed significant increase of TAG-72 and CEA levels in tumor biopsies from patients diagnosed with colorectal carcinoma and given systemic IFN-α (22). Those studies led to a clinical trial in which late stage breast cancer patients were administered interferon in combination with therapeutic doses of CC49. Some clinical responses were observed, however, the cytokine and MAb combination may have also enhanced marrow toxicity. Future studies will continue to evaluate the ability to enhance tumor antigen expression in the context of genetically engineered MAbs designed to minimize normal organ toxicity.

Original languageEnglish
Pages (from-to)2129-2133
Number of pages5
JournalAnticancer Research
Volume16
Issue number4 B
Publication statusPublished - Jul 1996

Fingerprint

Monoclonal Antibodies
Cytokines
Neoplasm Antigens
Neoplasms
Interferons
Therapeutics
Immunoconjugates
Dose Fractionation
Genetic Engineering
Ascites
Cellular Immunity
Colorectal Neoplasms
Pharmacokinetics
Perfusion
Bone Marrow
Research Personnel
Clinical Trials
Breast Neoplasms
Phenotype
Biopsy

Keywords

  • γ-detecting probe
  • γ-interferon
  • Immunodiagnosis
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. / Greiner, John W.; Guadagni, Fiorella; Roselli, Mario; Nieroda, Carol A.

In: Anticancer Research, Vol. 16, No. 4 B, 07.1996, p. 2129-2133.

Research output: Contribution to journalArticle

Greiner, John W. ; Guadagni, Fiorella ; Roselli, Mario ; Nieroda, Carol A. / Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine. In: Anticancer Research. 1996 ; Vol. 16, No. 4 B. pp. 2129-2133.
@article{0597ef6d29c74e28965ddd8bdb4c02c9,
title = "Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine",
abstract = "Cytokine-based tumor antigen augmentation is one of the approaches researchers and clinicians are using to improve the effectiveness of MAb-directed tumor diagnosis and therapy. Other efforts encompass the use of dose-fractionation for multiple administrations of radioimmunoconjugates, exploitation of genetic engineering to construct antibody molecules with specific biological properties (i.e., altered pharmacokinetics, activation of cellular immune responses, etc.) and use of MAb-directed conjugates that can enhance tumor MAb uptake by altering tumor perfusion (7, 19). The studies summarized here as well as those from other laboratories have served as the framework for clinical investigations designed to determine the effectiveness of the interferons and other differentiation-inducing agents to alter the tumor antigen phenotype in patients. In an earlier study, patients given IFN-α had improved tumor uptake of an antimelanoma MAb(20). Subsequently, we reported that i.p. IFN-γ administration substantially upregulated TAG-72 and CEA on the surface of human tumor cells isolated from malignant ascites (21). A seminal investigation showed significant increase of TAG-72 and CEA levels in tumor biopsies from patients diagnosed with colorectal carcinoma and given systemic IFN-α (22). Those studies led to a clinical trial in which late stage breast cancer patients were administered interferon in combination with therapeutic doses of CC49. Some clinical responses were observed, however, the cytokine and MAb combination may have also enhanced marrow toxicity. Future studies will continue to evaluate the ability to enhance tumor antigen expression in the context of genetically engineered MAbs designed to minimize normal organ toxicity.",
keywords = "γ-detecting probe, γ-interferon, Immunodiagnosis, Radioimmunotherapy",
author = "Greiner, {John W.} and Fiorella Guadagni and Mario Roselli and Nieroda, {Carol A.}",
year = "1996",
month = "7",
language = "English",
volume = "16",
pages = "2129--2133",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 B",

}

TY - JOUR

T1 - Novel approaches to tumor detection and therapy using a combination of monoclonal antibody and cytokine

AU - Greiner, John W.

AU - Guadagni, Fiorella

AU - Roselli, Mario

AU - Nieroda, Carol A.

PY - 1996/7

Y1 - 1996/7

N2 - Cytokine-based tumor antigen augmentation is one of the approaches researchers and clinicians are using to improve the effectiveness of MAb-directed tumor diagnosis and therapy. Other efforts encompass the use of dose-fractionation for multiple administrations of radioimmunoconjugates, exploitation of genetic engineering to construct antibody molecules with specific biological properties (i.e., altered pharmacokinetics, activation of cellular immune responses, etc.) and use of MAb-directed conjugates that can enhance tumor MAb uptake by altering tumor perfusion (7, 19). The studies summarized here as well as those from other laboratories have served as the framework for clinical investigations designed to determine the effectiveness of the interferons and other differentiation-inducing agents to alter the tumor antigen phenotype in patients. In an earlier study, patients given IFN-α had improved tumor uptake of an antimelanoma MAb(20). Subsequently, we reported that i.p. IFN-γ administration substantially upregulated TAG-72 and CEA on the surface of human tumor cells isolated from malignant ascites (21). A seminal investigation showed significant increase of TAG-72 and CEA levels in tumor biopsies from patients diagnosed with colorectal carcinoma and given systemic IFN-α (22). Those studies led to a clinical trial in which late stage breast cancer patients were administered interferon in combination with therapeutic doses of CC49. Some clinical responses were observed, however, the cytokine and MAb combination may have also enhanced marrow toxicity. Future studies will continue to evaluate the ability to enhance tumor antigen expression in the context of genetically engineered MAbs designed to minimize normal organ toxicity.

AB - Cytokine-based tumor antigen augmentation is one of the approaches researchers and clinicians are using to improve the effectiveness of MAb-directed tumor diagnosis and therapy. Other efforts encompass the use of dose-fractionation for multiple administrations of radioimmunoconjugates, exploitation of genetic engineering to construct antibody molecules with specific biological properties (i.e., altered pharmacokinetics, activation of cellular immune responses, etc.) and use of MAb-directed conjugates that can enhance tumor MAb uptake by altering tumor perfusion (7, 19). The studies summarized here as well as those from other laboratories have served as the framework for clinical investigations designed to determine the effectiveness of the interferons and other differentiation-inducing agents to alter the tumor antigen phenotype in patients. In an earlier study, patients given IFN-α had improved tumor uptake of an antimelanoma MAb(20). Subsequently, we reported that i.p. IFN-γ administration substantially upregulated TAG-72 and CEA on the surface of human tumor cells isolated from malignant ascites (21). A seminal investigation showed significant increase of TAG-72 and CEA levels in tumor biopsies from patients diagnosed with colorectal carcinoma and given systemic IFN-α (22). Those studies led to a clinical trial in which late stage breast cancer patients were administered interferon in combination with therapeutic doses of CC49. Some clinical responses were observed, however, the cytokine and MAb combination may have also enhanced marrow toxicity. Future studies will continue to evaluate the ability to enhance tumor antigen expression in the context of genetically engineered MAbs designed to minimize normal organ toxicity.

KW - γ-detecting probe

KW - γ-interferon

KW - Immunodiagnosis

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=0029795732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029795732&partnerID=8YFLogxK

M3 - Article

C2 - 8694532

AN - SCOPUS:0029795732

VL - 16

SP - 2129

EP - 2133

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 B

ER -